FIELD: biotechnology.
SUBSTANCE: presented in the invention are: pharmaceutical compositions containing an antibody against CD40 or an antigen-binding fragment thereof, and an application of said compositions; a lyophilised agent for treating diseases and a method for production thereof; and a kit for treating CD40-associated diseases or symptoms.
EFFECT: possibility of producing pharmaceutical compositions showing good antibody stability and used to effectively treat CD40-associated diseases or symptoms.
19 cl, 16 tbl, 15 ex
Title |
Year |
Author |
Number |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE |
2018 |
- Tian, Chenmin
- Li, Hao
- Liu, Xun
|
RU2782792C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE |
2018 |
- Wu Tingting
- Li Hao
- Liu Xun
- Fu Yayuan
|
RU2771384C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE |
2018 |
- Fang Jingjing
- Yan Zhen
- Liu Xun
|
RU2779430C2 |
PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION |
2019 |
- Tyan, Chenmin
- Li, Khao
- Lyu, Syun
|
RU2791683C2 |
PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION |
2018 |
- Yan, Zhen
- Yang, Jianjian
- Yan, Xiaodan
- Wu, Shan
- Liu, Xun
|
RU2766590C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF |
2020 |
- U, Tintin
- Li, Khao
- Lyu, Syun
- Tao, Vejkan
|
RU2824390C2 |
CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF |
2020 |
- Yang Yang
- Xu Jianyan
- Tao Weikang
|
RU2826119C1 |
ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE |
2018 |
- Yan, Shude
- Jiang, Jiahua
- Hu, Qiyue
- Zhang, Lianshan
- Cao, Guoqing
- Qian, Xueming
- Teng, Fei
|
RU2779128C2 |
ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE |
2020 |
- Gu Xiaoling
- Ye Xin
- Ge Hu
- Tao Weikang
|
RU2807484C2 |
ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF |
2020 |
- Yan, Yan
- Ge, Khu
- Tao, Vejkan
|
RU2822550C2 |